Taranis Capital have built an outstanding team of investor relations professionals who ensure every client receives a fast, personal service, based on diligence, transparency and responsiveness.
Taranis Capital’s investment thesis is centred on empowering innovative companies to scale rapidly and enter new markets with confidence. We focus on high-potential businesses where our capital, combined with our deep industry expertise and global network, can create oan utsized impact. Beyond funding, we provide strategic guidance, operational support, and direct market access, leveraging our connections across financial services, technology, and regulatory ecosystems. Our approach is not just to invest, but to actively partner with founders, helping them navigate complex market entry challenges, accelerate growth trajectories, and unlock new revenue opportunities. This hands-on, value-creation model enables our portfolio companies to achieve meaningful, sustained expansion far beyond what capital alone can deliver.
The global biotechnology industry is a trillion-dollar market, with a total addressable market of roughly $1.5 trillion in 2024. This sector spans tens of thousands of companies worldwide (approximately 20,000+ biotech firms), ranging from startups to large public players. Venture capital primarily targets the early-stage and growth-stage subset of these companies – typically small, R&D-focused drug developers. Major biotech hubs (the US, Europe, and China) each host thousands of firms, but all regions see robust innovation pipelines fueling new company growth.
Hundreds of new biotech startups form globally each year. Annual formation peaked during the 2020–2021 boom (around 400 new biotechs launched in 2021) as the pandemic accelerated investment in life sciences. In subsequent years, the pace moderated but remained strong: even in 2023’s downturn, an estimated 250–300 new biotech ventures were created worldwide. These early-stage startups often spin out of academia or pharma, targeting cutting-edge areas like gene therapy, AI-driven drug discovery, and oncology. Such steady new company formation ensures a continuous pipeline of young biotechs seeking VC funding.
Venture capital funding in biotech surged to record levels in 2020–2021, then corrected before recovering in 2024. Global VC investment in biotech was about $20–25 billion in 2020, then nearly doubled to around $40 billion in 2021 at the peak of pandemic-driven enthusiasm. Funding cooled to roughly $30 billion in 2022 and $23 billion in 2023 amid market pullbacks. In 2024, total biotech VC funding rebounded to ~$26 billion, breaking a two-year downtrend. Notably, investors concentrated capital into fewer deals – favoring large rounds for promising early-stage startups (several $100M+ Series A “mega-rounds”) – while growth-stage financings continued selectively. This backdrop of rising median deal sizes and renewed capital inflows in 2024 signals cautious optimism and sustained capacity for biotech innovation.
